<?xml version="1.0" encoding="UTF-8"?>
<p class="p">However, EO are highly volatile and can decompose easily due to direct exposure to heat, moisture, light, or oxygen [
 <xref rid="B18" ref-type="bibr" class="xref">18</xref>]. Nanoencapsulation represents a feasible and efficient alternative to overcome these drawbacks since it would provide stability to the active substance [
 <xref rid="B19" ref-type="bibr" class="xref">19</xref>], protection against oxidation [
 <xref rid="B20" ref-type="bibr" class="xref">20</xref>], retention of volatile compounds, and reduction of side effects [
 <xref rid="B20" ref-type="bibr" class="xref">20</xref>, 
 <xref rid="B21" ref-type="bibr" class="xref">21</xref>]. In recent years, there has been growing interest in the development of polymeric nanoparticles, particularly nanocapsules (NC), as systems for the administration of lipophilic bioactive components [
 <xref rid="B22" ref-type="bibr" class="xref">22</xref>], representing a new form of topical administration of EO with a preventive and/or therapeutic antioxidant effect. In this study, Eudragit EPO was used as the NC-formed polymer due to its cationic nature which will allow a greater interaction with the skin, as a result of the electrostatic interaction [
 <xref rid="B23" ref-type="bibr" class="xref">23</xref>].
</p>
